NEWS FEED & ADDITIVE MAGAZINE September 2025 11 Tiba Biotech LLC, which specializes in next-generation RNA medicines for human and animal health, announced the results of a challenge study evaluating the efficacy of a novel vaccine for Foot and Mouth Disease (FMD) in cattle. Conducted by Germany’s Friedrich Loeffler Institute, the study assessed both humoral immune responses and protective efficacy upon direct viral challenge exposure. All vaccinated animals were fully protected, showing no signs of viral shedding or adverse effects, the study shows. The vaccine was developed by Tiba scientists as part of an international research collaboration with the Elizabeth Macarthur Agricultural Institute and the RNA Institute at the University of New South Wales, with support from the NSW Department of Primary Industries and Regional Development (DPIRD) and Meat & Livestock Australia (MLA). This success builds on earlier livestock vaccine research supported by the Bill and Malinda Gates Foundation (BMGF) and Canada’s International Development Research Centre (IDRC). FMD remains an ongoing global threat, with recent outbreaks in Europe and endemic circulation in parts of Africa, Asia, and the Middle East. Modeling from the Australian Bureau of Agricultural and Resource Economics and Sciences (ABARES) has estimated an incursion could cost the Australian economy up to AUD80 billion. Read more>> New Study: Tiba’s novel vaccine protects cattle from Foot-and-Mouth Disease Photo: Freepik
RkJQdWJsaXNoZXIy MTUxNjkxNQ==